Cancer Genetics, Inc. Adds Additional Kidney Cancer Patent to its Portfolio

By Italia on February 26 2014

CGI Receives Notice of Allowance for Its Proprietary Kidney Cancer Test, Further Strengthening the Company’s IP Portfolio RUTHERFORD, N.J., Feb. 26, 2014 — Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, today announced that the United States Patent and Trademark Office (USPTO) has allowed its patent claims related to […]

Continue Reading

Cancer Genetics, Inc. Announces a New Breakthrough for Diagnosis and Prediction of Kidney Cancer Outcomes Using Its Proprietary Genomic Test

By Italia on February 24 2014

Significant Advancement in the Classification and Prediction of Kidney Cancer Outcomes Validated in Collaborative 191 Patient Clinical Study with Cleveland Clinic Using CGI’s Genomic Microarray Test New Data to Be Presented at USCAP Annual Meeting by Cleveland Clinic’s Dr. Magi-Galuzzi on Monday, March 3 RUTHERFORD, N.J., Feb. 24, 2014 (GLOBE NEWSWIRE) — Cancer Genetics, Inc. […]

Continue Reading

Cancer Genetics, Inc. New Clinical Trial Backlog Exceeds $13 Million

By Italia on February 20 2014

Rutherford, NJ – February 20, 2014 – Cancer Genetics, Inc. (NasdaqCM: CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, initiated two additional multi-year clinical trial contracts with biopharmaceutical customers. The Company estimates that the new contracts increase its total SelectOneTM pipeline to over $13 million in revenue over the next two years. CGI’s SelectOne program […]

Continue Reading

Cancer Genetics is Pleased to Announce The Appointment of Dr. Paul Rothman, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to its Board of Directors

By Jamie on February 18 2014

RUTHERFORD, NJ – February 18, 2014 – Cancer Genetics (NasdaqCM: CGIX), an emerging leader in DNA-based diagnostics, announced today the addition of Paul Rothman, MD, Dean of the Medical Faculty and CEO of Johns Hopkins Medicine, to the Company’s Board of Directors. As Dean and CEO, Dr. Rothman oversees both the Johns Hopkins Health System and the School of Medicine.  He […]

Continue Reading

Cancer Genetics to Provide Corporate Update at 16th Annual BIO CEO & Investor Conference in New York

By Jamie on February 10 2014

RUTHERFORD, NJ – February 10, 2014 – Cancer Genetics (NASDAQ: CGIX), an emerging leader in DNA-based diagnostics, announced today that Panna Sharma, President and Chief Executive Officer of Cancer Genetics, will provide a corporate overview at the BIO CEO & Investor Conference, being held at the Waldorf Astoria Hotel in New York City on February 10-11, […]

Continue Reading

Cancer Genetics, Inc. and Roche Announce Expanded, Exclusive International Agreement to Provide Molecular Diagnostic Cancer Testing

By Italia on February 10 2014

CGI Will Be the Exclusive Provider of Molecular Diagnostic Cancer Testing for Roche Servicios in Central America and the Caribbean CGI Will Develop A Center of Excellence for Lung Cancer Testing Utilizing the FDA-Approved cobas® Platform RUTHERFORD, NJ (February  10, 2014): Cancer Genetics, Inc. (NASDAQ:CGIX) (“CGI” or the “Company”), an emerging leader in DNA-based diagnostics, and Roche […]

Continue Reading